|
 |
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Molecular & Cellular Proteomics 6:2212-2229, 2007.
© 2007 by The American Society for Biochemistry and Molecular Biology, Inc.
Research
Quantitative, Multiplexed Assays for Low Abundance Proteins in Plasma by Targeted Mass Spectrometry and Stable Isotope Dilution*,S
From the Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts 02142
Biomarker discovery produces lists of candidate markers whose presence and level must be subsequently verified in serum or plasma. Verification represents a paradigm shift from unbiased discovery approaches to targeted, hypothesis-driven methods and relies upon specific, quantitative assays optimized for the selective detection of target proteins. Many protein biomarkers of clinical currency are present at or below the nanogram/milliliter range in plasma and have been inaccessible to date by MS-based methods. Using multiple reaction monitoring coupled with stable isotope dilution mass spectrometry, we describe here the development of quantitative, multiplexed assays for six proteins in plasma that achieve limits of quantitation in the 1–10 ng/ml range with percent coefficients of variation from 3 to 15% without immunoaffinity enrichment of either proteins or peptides. Sample processing methods with sufficient throughput, recovery, and reproducibility to enable robust detection and quantitation of candidate biomarker proteins were developed and optimized by addition of exogenous proteins to immunoaffinity depleted plasma from a healthy donor. Quantitative multiple reaction monitoring assays were designed and optimized for signature peptides derived from the test proteins. Based upon calibration curves using known concentrations of spiked protein in plasma, we determined that each target protein had at least one signature peptide with a limit of quantitation in the 1–10 ng/ml range and linearity typically over 2 orders of magnitude in the measurement range of interest. Limits of detection were frequently in the high picogram/milliliter range. These levels of assay performance represent up to a 1000-fold improvement compared with direct analysis of proteins in plasma by MS and were achieved by simple, robust sample processing involving abundant protein depletion and minimal fractionation by strong cation exchange chromatography at the peptide level prior to LC-multiple reaction monitoring/MS. The methods presented here provide a solid basis for developing quantitative MS-based assays of low level proteins in blood.
To whom correspondence should be addressed. Tel.: 617-324-9762; Fax: 617-252-1902; E-mail: scarr{at}broad.mit.edu
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. W. Buczynski, D. S. Dumlao, and E. A. Dennis Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology J. Lipid Res., June 1, 2009; 50(6): 1015 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kuhn, T. Addona, H. Keshishian, M. Burgess, D.R. Mani, R. T. Lee, M. S. Sabatine, R. E. Gerszten, and S. A. Carr Developing Multiplexed Assays for Troponin I and Interleukin-33 in Plasma by Peptide Immunoaffinity Enrichment and Targeted Mass Spectrometry Clin. Chem., June 1, 2009; 55(6): 1108 - 1117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Anderson, N. G. Anderson, T. W. Pearson, C. H. Borchers, A. G. Paulovich, S. D. Patterson, M. Gillette, R. Aebersold, and S. A. Carr A Human Proteome Detection and Quantitation Project Mol. Cell. Proteomics, May 1, 2009; 8(5): 883 - 886. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Anderson, A. Jackson, D. Smith, D. Hardie, C. Borchers, and T. W. Pearson SISCAPA Peptide Enrichment on Magnetic Beads Using an In-line Bead Trap Device Mol. Cell. Proteomics, May 1, 2009; 8(5): 995 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fortin, A. Salvador, J. P. Charrier, C. Lenz, X. Lacoux, A. Morla, G. Choquet-Kastylevsky, and J. Lemoine Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests Mol. Cell. Proteomics, May 1, 2009; 8(5): 1006 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Mead, L. Bianco, V. Ottone, C. Barton, R. G. Kay, K. S. Lilley, N. J. Bond, and C. Bessant MRMaid, the Web-based Tool for Designing Multiple Reaction Monitoring (MRM) Transitions Mol. Cell. Proteomics, April 1, 2009; 8(4): 696 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Yocum and A. M. Chinnaiyan Current affairs in quantitative targeted proteomics: multiple reaction monitoring-mass spectrometry Brief Funct Genomic Proteomic, March 11, 2009; (2009) eln056v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Ye, J. Blonder, and T. D. Veenstra Targeted proteomics for validation of biomarkers in clinical samples Brief Funct Genomic Proteomic, March 1, 2009; 8(2): 126 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kuno, Y. Kato, A. Matsuda, M. K. Kaneko, H. Ito, K. Amano, Y. Chiba, H. Narimatsu, and J. Hirabayashi Focused Differential Glycan Analysis with the Platform Antibody-assisted Lectin Profiling for Glycan-related Biomarker Verification Mol. Cell. Proteomics, January 1, 2009; 8(1): 99 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Carr and L. Anderson Protein Quantitation through Targeted Mass Spectrometry: The Way Out of Biomarker Purgatory? Clin. Chem., November 1, 2008; 54(11): 1749 - 1752. [Full Text] [PDF]
|
|
|
|
|
|
A. N. Hoofnagle, J. O. Becker, M. H. Wener, and J. W. Heinecke Quantification of Thyroglobulin, a Low-Abundance Serum Protein, by Immunoaffinity Peptide Enrichment and Tandem Mass Spectrometry Clin. Chem., November 1, 2008; 54(11): 1796 - 1804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. R. Nicol, M. Han, J. Kim, C. E. Birse, E. Brand, A. Nguyen, M. Mesri, W. FitzHugh, P. Kaminker, P. A. Moore, et al. Use of an Immunoaffinity-Mass Spectrometry-based Approach for the Quantification of Protein Biomarkers from Serum Samples of Lung Cancer Patients Mol. Cell. Proteomics, October 1, 2008; 7(10): 1974 - 1982. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. Jaffe, H. Keshishian, B. Chang, T. A. Addona, M. A. Gillette, and S. A. Carr Accurate Inclusion Mass Screening: A Bridge from Unbiased Discovery to Targeted Assay Development for Biomarker Verification Mol. Cell. Proteomics, October 1, 2008; 7(10): 1952 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-J. Qian, D. T. Kaleta, B. O. Petritis, H. Jiang, T. Liu, X. Zhang, H. M. Mottaz, S. M. Varnum, D. G. Camp II, L. Huang, et al. Enhanced Detection of Low Abundance Human Plasma Proteins Using a Tandem IgY12-SuperMix Immunoaffinity Separation Strategy Mol. Cell. Proteomics, October 1, 2008; 7(10): 1963 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Decramer, A. G. de Peredo, B. Breuil, H. Mischak, B. Monsarrat, J.-L. Bascands, and J. P. Schanstra Urine in Clinical Proteomics Mol. Cell. Proteomics, October 1, 2008; 7(10): 1850 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Gerszten, F. Accurso, G. R. Bernard, R. M. Caprioli, E. W. Klee, G. G. Klee, I. Kullo, T. A. Laguna, F. P. Roth, M. Sabatine, et al. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI Clinical Proteomics Programs Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L16 - L22. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Journal of Lipid Research | ASBMB Today |